CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Very Low Dose Quillivant XR +2 moredrug
Likely dose
Very Low Dose Quillivant XR 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02255565
NCT02255565Phase 4Completed
CompareCT.gov

Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study

Seattle Children's Hospital·interventional·Posted Oct 2, 2014·Updated Aug 1, 2017

In Brief

A Phase 4 clinical trial evaluating Very Low Dose Quillivant XR, Low Dose Quillivant XR, and 1 other intervention for ADHD and Autism. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD, Autism
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.8 years ago

Interventions

Very Low Dose Quillivant XRdrug

Oral suspension dose once a day increasing to a 10mg dose

Low Dose Quillivant XRdrug

Oral suspension dose once a day increasing to a 20mg dose

Moderate Dose Quillivant XRdrug

Oral suspension dose once a day increasing to a 40mg dose